PO2/01 Changes to the provision of services for people who inject drugs in England, Wales and Northern Ireland during the COVID-19 pandemic
S. Croxford , E. Emanuel , A. Ibitoye, J. Njoroge, C. Edmundson, L. Slater, E. Phipps

PO2/02 COVID-19 impact on harm reduction programs (testing and counselling) in low threshold drug services in Germany
A. Krings, G. Steffen, C. Germershausen, R. Zimmermann

PO2/03 The impact of the COVID-19 pandemic on harm reduction services in a prison and addiction centres in the Balearic Islands, Spain: preliminary results from a novel hepatitis C elimination programme
A. Herranz, À. Vilella, A. Agius, J.M. Alonso, A. Rodríguez, C.A Picchio, D. Guy, C. Pujol, M. Buti, J. Lazarus

PO2/04 Using peer support to facilitate hepatitis C treatment during the COVID-19 pandemic
J.S. Lambert, B. West, T. McHugh, J. Farrell, C. Moran, l. Vidal